TICKERNERD
Menu
TRVITRVIHealthcare · Biotechnology

TRVI Stock Forecast: Trevi Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 12 Aug 2026
$18
−0.39% on the day

The 11 Wall Street analysts covering Trevi Therapeutics, Inc. hold a median 12-month price target of $25 — +41.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 53 of 100 as at 12 Aug 2026 — in the upper half.

Market cap
$2.5B
Ticker Nerd rank
53 / 100
Median analyst target
$25
Analysts covering
11
Total return, dividends reinvested
1W
−4.9%
1M
−0.6%
YTD
+41.6%
1Y
+141.9%
From 52W high
−9.1%
From 52W low
+152.9%
$7
$20
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

TRVI stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Trevi Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Aug 2026
53 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
97
Value
81
Volatility
69
Quality
67
Growth
41
Issuance
37
Revisions
34
Size
33
Accruals
33

Momentum (97): The shares have been drifting up relative to others.

Accruals (33): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

TRVI stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on TRVI, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$20$30$40Oct 25Jan 26Apr 26Jul 26TRVIHigh $40Median $25Low $23

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says11 analysts
11 Buy0 Hold0 Sell
Low $23Median $25High $40

The green dot is the last close — the median target sits +41.0% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 4 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
7 Aug 2026Cantor FitzgeraldMaintainsOverweight$25 → $30
7 Aug 2026OppenheimerMaintainsOutperform$24 → $25
21 July 2026BMO CapitalInitiatesOutperform—
21 July 2026BMO CapitalInitiatesOutperform$36
20 July 2026B. Riley SecuritiesMaintainsBuy$21 → $31
20 July 2026B. Riley SecuritiesMaintainsBuy—
20 July 2026HC Wainwright & Co.MaintainsBuy—
20 July 2026HC Wainwright & Co.MaintainsBuy$21 → $24
20 May 2026NeedhamReiteratesBuy$23
20 May 2026NeedhamReiteratesBuy—
6 May 2026HC Wainwright & Co.ReiteratesBuy—
6 May 2026NeedhamMaintainsBuy—
17 Apr 2026D. Boral CapitalMaintainsBuy—
19 Mar 2026Jones TradingMaintainsBuy—
18 Mar 2026D. Boral CapitalMaintainsBuy—
18 Mar 2026Morgan StanleyMaintainsOverweight—
18 Mar 2026NeedhamMaintainsBuy—
9 Mar 2026D. Boral CapitalMaintainsBuy—
9 Mar 2026HC Wainwright & Co.ReiteratesBuy—
9 Jan 2026HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. TRVI appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

TRVI analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
3
Analysts cutting
1
Fundamentals

Trevi Therapeutics, Inc. (TRVI) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−55.6×

Cheaper than 98% of US stocks

Price / sales
—
Price / book
13.3×

Cheaper than 8% of US stocks

EV / EBITDA
−37.3×

Cheaper than 92% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 33% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−19.7%

Higher than 31% of US stocks

Return on assets
−13.8%

Higher than 24% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

TRVI vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
TRVITrevi Therapeutics, Inc.$2.5B
53
NKTRNektar Therapeutics$2.5B
54
PHVSPharvaris NV$2.5B
42
VRDNViridian Therapeutics, Inc.$2.5B
41
COAGHemab Therapeutics Holdings, Inc.$2.5B
2
KODKodiak Sciences, Inc.$2.6B
58
PGENPrecigen, Inc.$2.4B
84

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Trevi Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest TRVI news & analysis

Trevi Therapeutics Q2 Earnings Call Highlights

MarketBeat · 7 Aug 2026positive

Trevi Therapeutics reported in its Q2 earnings call that it began two clinical trials during the second quarter for Haduvio (nalbuphine ER), targeting multiple chronic-cough indications, and plans to launch a third study in the third quarter.

Why it matters — TRVI watchers would care because the advancement of multiple clinical trials signals continued progress in expanding Haduvio's development pipeline for chronic-cough indications.

Trevi Therapeutics, Inc. (TRVI) Q2 2026 Earnings Call Transcript

Seeking Alpha · 6 Aug 2026neutral

Trevi Therapeutics, Inc. held its Q2 2026 earnings call, during which management discussed the company's financial results and operational progress for the quarter.

Why it matters — TRVI watchers would care because the earnings call provides management's perspective on the company's quarterly performance and strategic direction.

Trevi Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates

GlobeNewsWire · 6 Aug 2026neutral

Trevi Therapeutics reported its second quarter 2026 financial results and provided business updates. The company initiated the Phase 3 OCEAN-1 trial for idiopathic pulmonary fibrosis-related chronic cough in the second quarter, and the Phase 3 OCEAN-2 trial is expected to start in the third quarter of 2026.

Why it matters — TRVI watchers would follow this update because it confirms the company is advancing its Phase 3 clinical program for the chronic cough indication.

Trevi Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 6, 2026

GlobeNewsWire · 30 July 2026neutral

Trevi Therapeutics announced that senior management will host a conference call and webcast on August 6, 2026, to discuss second quarter 2026 financial results and provide a corporate update.

Why it matters — Investors tracking TRVI will want to hear the company's latest financial results and any updates on the development of Haduvio for chronic cough indications.

Trevi Therapeutics to Participate in Upcoming August Conferences

GlobeNewsWire · 28 July 2026neutral

Trevi Therapeutics announced that its senior management will participate in multiple conferences scheduled for August.

Why it matters — A TRVI watcher would care because these conference appearances provide opportunities for management to present the company's pipeline and engage with investors and industry peers.

FAQ

Frequently asked questions about TRVI stock

What is the TRVI stock price forecast for 2026-2027?

The 11 Wall Street analysts covering Trevi Therapeutics, Inc. have a median 12-month price target of $25, with estimates ranging from $23 to $40. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is TRVI stock a buy right now?

Of the 11 analysts covering Trevi Therapeutics, Inc., 11 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Trevi Therapeutics, Inc. 53 out of 100 across roughly 4,600 US stocks as at 12 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank TRVI?

As at 12 Aug 2026, Trevi Therapeutics, Inc. ranks 53 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (97 of 100).

Will TRVI stock go up?

No one can know that. What the data says: the median 12-month target from 11 analysts implies +41.0% from the last close, and Ticker Nerd's factor model ranks Trevi Therapeutics, Inc. 53 out of 100 as at 12 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the TRVI stock forecast for 2030?

No analyst covering Trevi Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TRVI are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $23 to $40 over the next 12 months.

How has TRVI stock performed over the past year?

Trevi Therapeutics, Inc. returned +141.9% over the 12 months to 12 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Trevi Therapeutics, Inc. do?

Trevi Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing Haduvio, an oral extended-release formulation of nalbuphine, for treating chronic cough in patients with idiopathic pulmonary fibrosis, non-IPF interstitial lung disease, and refractory chronic cough.

What is the latest news on TRVI?

The most recent item we track (MarketBeat, 7 Aug 2026): "Trevi Therapeutics Q2 Earnings Call Highlights". Trevi Therapeutics reported in its Q2 earnings call that it began two clinical trials during the second quarter for Haduvio (nalbuphine ER), targeting multiple chronic-cough indications, and plans to launch a third study in the third quarter.

Company

About Trevi Therapeutics, Inc.

Trevi Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing Haduvio, an oral extended-release formulation of nalbuphine, for treating chronic cough in patients with idiopathic pulmonary fibrosis, non-IPF interstitial lung disease, and refractory chronic cough. Haduvio acts as a kappa opioid receptor agonist and mu opioid receptor antagonist, targeting the cough reflex arc both centrally and peripherally to address nerve hypersensitivity underlying these conditions, where no approved therapies exist in the U.S. The company is advancing Haduvio through late-stage clinical trials, including positive Phase 2b results demonstrating statistically significant reductions in cough frequency. Trevi Therapeutics Inc. operates in the biotechnology sector, concentrating on neurologically mediated cardiorespiratory diseases that impose substantial burdens on patients, caregivers, and healthcare systems. Founded in 2011 and headquartered in New Haven, Connecticut, the company leverages its expertise in opioid receptor modulation to deliver novel investigational therapies for unmet medical needs in chronic cough management.

CEO Ms. Jennifer L. Good · 34 employees · United States · https://www.trevitherapeutics.com